Results 181 to 190 of about 11,407 (210)

Mutant prevention concentrations, <i>in vitro</i> resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible <i>Klebsiella pneumoniae</i> isolates showing ceftazidime/avibactam resistance. [PDF]

Antimicrob Agents Chemother
Blanco-Martín T, González-Pinto L, Aja-Macaya P, Rodríguez-Pallares S, Sánchez-Peña L, Gato E, Fernández-López MdC, Outeda-García M, Rodríguez-Coello A, Pedraza-Merino R, Alonso-García I, Vázquez-Ucha JC, Martínez-Martínez L, Arca-Suárez J, Beceiro A, Bou G.   +15 more
europepmc   +1 more source

Evolution of ceftazidime-avibactam resistance driven by mutations in double-copy bla_KPC-2 to bla_KPC-189 during treatment of ST11 carbapenem-resistant Klebsiella pneumoniae. [PDF]

mSystems
Zhang X, Xie Y, Zhang Y, Lei T, Zhou L, Yao J, Liu L, Liu H, He J, Yu Y, Tu Y, Li X.   +11 more
europepmc   +1 more source

Klebsiella pneumoniae carbapenemase variant 44 acquires ceftazidime-avibactam resistance by altering the conformation of active-site loops. [PDF]

J Biol Chem
Sun Z, Lin H, Hu L, Neetu N, Sankaran B, Wang J, Prasad BVV, Palzkill T.   +7 more
europepmc   +1 more source

New antibiotics for bad bugs: where are we? [PDF]

core   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview

Antimicrobial Agents and Chemotherapy, 2022
First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have encountered a worldwide success, particularly in K. pneumoniae isolates. These beta-lactamases conferred resistance to most beta-lactams including carbapenems but remained susceptible to new beta-lactam ...
Hobson, Claire Amaris, Pierrat, Gautier, Tenaillon, Olivier, Bonacorsi, Stéphane, Bercot, Béatrice, Jaouen, Ella, Jacquier, Hervé, Birgy, André   +7 more
openaire   +6 more sources

Predictors of Resistance to Ceftazidime-Avibactam in Carbapenem-Resistant Enterobacterales

Infectious Diseases in Clinical Practice, 2022
Background Ceftazidime-avibactam (CAZ-AVI) is a safe and effective treatment option for carbapenem-resistant Enterobacterales (CRE). However, predictors of resistance to CAZ-AVI have not been well defined. Therefore, our study describes risk factors for resistance to CAZ-AVI in hospitalized patients with CRE infections.
Tae Eun Park, Eris Cani, Paul Kelly, Lendelle Raymond, Banibrata Roy, Cosmina Zeana, Anupama Menon   +6 more
openaire   +1 more source

The primary pharmacology of ceftazidime/avibactam: resistancein vitro

Journal of Antimicrobial Chemotherapy, 2023
AbstractThis article reviews resistance to ceftazidime/avibactam as an aspect of its primary pharmacology, linked thematically with recent reviews of the basic in vitro and in vivo translational biology of the combination (J Antimicrob Chemother 2022; 77: 2321–40 and 2341–52).
Wright W Nichols, Sushmita D Lahiri, Patricia A Bradford, Gregory G Stone   +3 more
openaire   +2 more sources